**Media Interview Guide**

Conducting a media interview can be intimidating, but with a little planning you can deliver quality information to media outlets. Review the information below to help you plan for an interview explaining the Hybrid AF™ Therapy and its impact on patients.

**Know Your Key Points**

Create a simple and concise outline of the key points you want to convey in the interview. Take into account who is interviewing you and who their audience is. Why do they care about Hybrid AF Therapy? Interviews often last only a few minutes. Know your message and deliver it quickly and clearly. It can help to practice your points beforehand with a colleague. (See the **Key Points,** p. 2.)

**Give Added Weight to Your Points**

Begin statements with phrases such as “What we’re focused on …” and “The most important factor is ...” to create a strong lead into your key points.

**Bring the Conversation Back**

An interviewer may not ask questions directly related to your key points, but you still need to get to your message with the little time you have. Use this as an opportunity to answer the question in a way that brings you back to one of your key points.

* *Reporter: “My aunt has heart failure. Should she get checked for Afib?”*
* *Interviewee: “Even though your aunt may have never felt symptoms of Afib, we often see a strong link between heart failure and AF. She should talk to her doctor about it, since we know 1 in 4 people over the age of 40 will develop AF during their lifetime."1*

**Navigate Tough Questions**

* The interviewer is tasked with telling the whole story, not just putting a positive spotlight on your hospital or treatment, and s/he might ask difficult questions of safety and efficacy. Be prepared for these types of questions. In your response, be sure to politely answer the question with your perspective and bring it back to your key messages whenever possible, ending on a positive note.
* Consider everything you say before, during and after an interview to be “on the record.”

**Suggested Talking Points**

**What Is Hybrid AF Therapy?**

* The first ever prospective, multi-center, randomized, controlled trial to focus on treating advanced AF patients with a hybrid AF therapy approach. This is the highest level of evidence.
* To treat atrial fibrillation (AF, Afib), people may have heard of endocardial catheter ablation, which treats the inside of the heart. Now the Hybrid AF CONVERGE RCT trial shows how effective Hybrid AF Therapy may be for these patients. Hybrid AF Therapy combines endocardial ablation with epicardial ablation, which treats the exterior of the heart.
* In this way Hybrid AF Therapy targets **two key trigger** **areas** where atrial fibrillation usually begins: the pulmonary veins inside and the back wall on the outside of the heart.

**Millions of People Need Treatment**

* **Key Point #1:** 1 in 4 adults over age 40 will develop AF in their lifetime1 which causes a **5x** increase in stroke risk.2
* **Key Point #2:** AF affects about 33 million people worldwide3 and 8 million people in the U.S4. More than 3.5 million of those people in the U.S. have advanced AF called long-standing persistent AF.4

**This Treatment Is More Effective**

* **Key Point #3:** For people with advanced stages of AA, catheter ablation alone often does not work well, even with repeat ablations.5 But Hybrid AF Therapy—which combines ablation on both sides of the heart wall—**can** be a lasting solution to long-standing persistent AF.6
* **Key Point #4:** In fact compared to catheter ablation alone, these are some of the 18-month findings with Hybrid AF Therapy:6,7
  + It was **2x more effective** at stopping AF—among patients who didn't get extra rhythm control medication.
  + Patients were **more than** **twice** as likely to no longer need AF medications.
  + Most people spend **at least 90% less time** in atrial fibrillation at 1 year.
* **Key Point #5:** People in the Hybrid AF Arm report feeling better, both physically and emotionally.7

Data based on the post-hoc analysis of long-standing persistent AF sub-groups (N=65)

**Who Would Benefit from This Therapy?**

* People who have long-standing persistent AF. These people have had atrial fibrillation that has lasted for over a year without stopping.
* It's important to note that AF progresses from mild to more severe forms. Without effective treatment, a case of mild, or paroxysmal, AF can eventually become long-standing persistent AF.
* Historically, people with this more severe form of atrial fibrillation had few options to stop their AF. That's why this new Hybrid AF Therapy is so important.

**Treating AF Is Always Very Important Because**

* It's a progressive disease.
* Atrial fibrillation puts a person at **5x** higher risk of stroke2 and **5x** greater risk of heart failure8.
* It is also associated with being less active and a diminished quality of life.9

**What Patients Should Know**

The symptoms for early stage and advanced stage AF are different. Symptoms for advanced AF:9,10

* Shortness of breath
* Lightheadedness
* Fainting
* Weakness
* Lack of energy
* Chest pain or angina

**What Patients Should Do**

* Talk to their doctor to find out what treatment is best for them.
* Once they've had treatment for AF, if symptoms continue, talk once again to their doctor about treatment.
* It's important for each person to find an effective treatment that can stop atrial fibrillation, so that it doesn't progress and become worse.

***EPi-Sense® Guided Coagulation System***

***U.S. Indications****: The EPi-Sense Guided Coagulation System is intended for the treatment of symptomatic long-standing persistent atrial fibrillation (continuous atrial fibrillation greater than 12 months duration) when augmented in a hybrid procedure with an endocardial catheter listed in the instructions for use, in patients (1) who are refractory or intolerant to at least one Class I and/or III antiarrhythmic drug (AAD); and (2) in whom the expected benefit from rhythm control outweighs the potential known risks associated with a hybrid procedure such as delayed post-procedure inflammatory pericardial effusions.* ***Contraindications*** *include patients with Barrett’s Esophagitis, left atrial thrombus, a systemic infection, active endocarditis, or a localized infection at the surgical site at the time of surgery.* ***Adverse Events****: Reported adverse events associated with epicardial ablation procedure may include, but are not limited to, the following: pericardial effusion/cardiac tamponade, pericarditis, excessive bleeding, phrenic nerve injury, stroke/TIA/neurologic complication. Please review the Instructions for Use for a complete listing of contraindications, warnings, precautions and potential adverse events located at the following AtriCure web address: https://www.AtriCure.com/EPi-Sense-Coagulation-Device.* ***Warnings****: Physicians should consider post-operative anti-inflammatory medication to decrease the potential for post-operative pericarditis. and/or delayed post-procedure inflammatory pericardial effusions. Physicians should consider post-procedural imaging (i.e. 1-3 weeks post-procedure) for detection of post-procedure inflammatory pericardial effusions.* ***Precautions****: Precautionary measures should be taken prior to considering treatment of patients: (1) Deemed to be high risk and who may not tolerate a potential delayed post-procedure inflammatory pericardial effusion. (2) Who may not be compliant with needed follow-ups to identify potential safety risks. To ensure patients undergoing treatment with the EPi-Sense device are well informed, the benefits, potential risks and procedural outcomes associated with the EPi-Sense Hybrid Convergent procedure should be discussed with the patient. Physicians should document accordingly in the medical record. Qualified operators are physicians authorized by their institution to perform surgical sub-xyphoid pericardial access. The coagulation devices should be used by physicians trained in the techniques of minimally invasive endoscopic surgical procedures and in the specific approach to be used. Operators should undergo training on the use of EPi-Sense device before performing the procedure. Safety and effectiveness of concomitant left atrial appendage closure was not evaluated in the CONVERGE study. Follow-up should be conducted at approximately 30 days post-procedure to monitor for signs of delayed onset pericarditis or pericardial effusion.* ***Rx Only.***

**Sources**

1. Lloyd-Jones, D.M., et al. (2004). Lifetime risk for development of atrial fibrillation. *Circulation,* 110, 1042-1046. doi: 10.1161/01.CIR.0000140263.20897.42

2. Benjamin, E.J., et al. (2019). Heart Disease and Stroke Statistics — 2019 Update: A Report From the American Heart Association. *Circulation,* 139m e56-e528, DOI: 10.1161/CIR.0000000000000659

3. Rahman, F., et al. (2014). Global epidemiology of atrial fibrillation. *Nature reviews cardiology,* 11, 639-654. https://doi.org/10.1038/nrcardio.2014.118

4. Colilla, S. et al. (2013). Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. *American journal of cardiology,* 112(8), 1142-1147.

5. Zembala, M., et al. (2017). Staged hybrid ablation for persistent and longstanding persistent atrial fibrillation effectively restores sinus rhythm in long-term observation. *Archives of medical science : AMS,* 13(1), 109–117. https://doi.org/10.5114/aoms.2015.53960

6. DeLurgio, D.B., et al. (2021). *Hybrid epicardial-endocardial RF ablation vs. endocardial catheter ablation for long-standing persistent atrial fibrillation treatment: Results from CONVERGE randomized controlled trial.* International AF Symposium.

7. AtriCure. (2020). *PMA P200002 FDA Instructions For Use: Epi-Sense® Guided Coagulation System.*

8. Odutayo, A. et al. (2016). Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. *BMJ,* 354, i4482.

9. Calkins, H. et al. (2018). 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation. *Heart rhythm,* 14(10):e275-444.

10. Barbarossa, A., et al. (2014). Silent atrial fibrillation: a critical review. *Journal of atrial fibrillation,* 7(3), 1138. http://www.jafib.com/PMC/XML/Inprogress/1138/1138pdf\_federico\_guerra.pdf.

PM-US-1500A-0123-G